UK markets close in 47 minutes

Perimeter Medical Imaging AI, Inc. (PYNKF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
2.6875-0.0025 (-0.09%)
As of 9:36AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close2.6900
Open2.6700
BidN/A x N/A
AskN/A x N/A
Day's range2.6700 - 2.6875
52-week range0.2200 - 4.0700
Volume880
Avg. volume19,196
Market cap114.53M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Perimeter Medical Imaging AI Reports 2020 Financial Results and Provides Corporate Update
    Business Wire

    Perimeter Medical Imaging AI Reports 2020 Financial Results and Provides Corporate Update

    Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) ("Perimeter" or the "Company"), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, today reported financial results for the year ended December 31, 2020 and provided a corporate update.

  • Perimeter Medical Imaging AI to Present at 2021 Bloom Burton & Co. Healthcare Investor Conference
    Business Wire

    Perimeter Medical Imaging AI to Present at 2021 Bloom Burton & Co. Healthcare Investor Conference

    Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) ("Perimeter" or the "Company"), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need, today announced that Jeremy Sobotta, Perimeter’s Chief Executive Officer, will present a company overview at the 2021 Bloom Burton & Co. Healthcare Investor Conference on Wednesday, April 21, 2021 at 4:00 p.m. ET.

  • Perimeter Medical Imaging AI Receives U.S. FDA Breakthrough Device Designation for its Optical Coherence Tomography (OCT) Imaging System with ImgAssist AI
    Business Wire

    Perimeter Medical Imaging AI Receives U.S. FDA Breakthrough Device Designation for its Optical Coherence Tomography (OCT) Imaging System with ImgAssist AI

    Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) ("Perimeter" or the "Company"), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, announced today that the U.S. Food and Drug Administration (FDA) has granted the company a Breakthrough Device Designation for its Optical Coherence Tomography (OCT) Imaging System coupled with ImgAssist AI. Perimeter is advancing its proprietary, next-gen artificial intelligence technology and machine learning tools through clinical development under its ATLAS AI project, which is made possible, in part, by a $7.4 million grant awarded by the Cancer Prevention and Research Institute of Texas (CPRIT), a leading state body funding cancer research.